Regeneron Pharmaceuticals, Inc.
Case Overview
32 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 09/14/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Regeneron Pharmaceuticals, Inc. |
| Court: | Court: Southern District of New York |
| Case Number: | Case Number: 7:26cv06026 |
| Class Period: | Class Period: 08/01/2025 - 05/15/2026 |
| Ticker: | Ticker: REGN |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
Defendants allegedly provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Regeneron's Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
On April 29, 2026, during Regeneron's first quarter earnings call, defendants disclosed the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." On this news, the price of Regeneron's common stock declined from a closing price of $731.77 per share on April 28, 2026 to $686.36 per share on April 29, 2026, or approximately 6.2%.
Then, on May 15, 2026, Regeneron issued a press release announcing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, the price of Regeneron's common stock declined from a closing price of $698.25 per share on May 15, 2026 to $629.68 per share on May 18, 2026, or approximately 9.8%.
On April 29, 2026, during Regeneron's first quarter earnings call, defendants disclosed the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." On this news, the price of Regeneron's common stock declined from a closing price of $731.77 per share on April 28, 2026 to $686.36 per share on April 29, 2026, or approximately 6.2%.
Then, on May 15, 2026, Regeneron issued a press release announcing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, the price of Regeneron's common stock declined from a closing price of $698.25 per share on May 15, 2026 to $629.68 per share on May 18, 2026, or approximately 9.8%.